Reassessment of the Use of Desferrioxamine B in Iron Overload

New England Journal of Medicine

Volumn 294, Issue 26, 1976, Pages 1421-1423

  Propper, Richard D ^a   Shurin, Susan B ^a   Nathan, David G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; DEFEROXAMINE MESYLATE; IRON;

BLOOD TRANSFUSION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; THALASSEMIA; URINE;

EID: 0017077213     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM197606242942603     Document Type: Article

References (18)

1. Finch C.A.: Iron metabolism in hemochromatosis. J Clin Invest 28: 780–781, 1949
2. Davis W.D. Jr., Arrowsmith W.R.: The treatment of hemochromatosis by massive venesection. Ann Intern Med 39: 723–734, 1953
3. Weintraub L.R., Conrad M.E., Crosby W.H.: The treatment of hemochromatosis by phlebotomy. Med Clin North Am 50: 1579–1590, 1966
4. Engle M.A.: Cardiac involvement in Cooley's anemia. Ann N.Y. Acad Sci 119: 694–702, 1964
5. Engle M.A., Erlandson M, Smith C.H.: Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation 30: 698–705, 1964
6. Bickel H. Gäumann E, Keller-Schierlein W, et al: Über eisenhaltige Wachstumsfaktoren, die Sideramine, und ihre Antagonisten, die eisenhaltigen Antibiotika Sideromycine. Experientia 16: 129–133, 1960
7. Modell C.B., Beck J: Long-term desferrioxamine therapy in thalassemia. Ann N.Y. Acad Sci 232: 201–210, 1974
8. Seshadri R, Colebatch J.H., Gordon P, et al: Long-term administration of desferrioxamine in thalassemia major. Arch Dis Child 49: 621–626, 1974
9. Constantoulakis M, Economidou J, Karagiorga M, et al: Combined long-term treatment of hemosiderosis with desferrioxamine and D.T.P.A in homozygous β-thalassemia. Ann N.Y. Acad Sci 232: 193–200, 1974
10. Wapnick A.A., Lynch S.R., Charlton R.W., et al: The effect of ascorbic acid deficiency on desferrioxamine-induced urinary iron excretion. Br J Haematol 17: 563–568, 1969
11. O'Brien R.T.: Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major. Ann N.Y. Acad Sci 232: 221–225, 1974
12. Lipschitz D.A., Dugard J, Simon M.O., et al: The site of action of desferrioxamine. Br J Haematol 20: 395–404, 1971
13. Hedenberg L: Studies on iron metabolism with desferrioxamine in man: experimental and clinical studies. Scand J Haematol: Suppl: 6: 5–86, 1969
14. Nienhuis A, Delea C, Aamodt R, et al: Potential role for desferrioxamine and ascorbic acid in the treatment of chronic iron overload. Presented at the Eighteenth Annual Meeting of the American Society of Hematology, Dallas, Texas, December 6–9, 1975
15. Hwang Y-F, Brown E.B.: Evaluation of deferoxamine in iron overload. Arch Intern Med 114: 741–753, 1964
16. Barry M, Flynn D.M., Letsky E.A., et al: Long-term chelation therapy in thalassemia major: effect on liver iron concentration, liver histology, and clinical progress. Br Med J 2: 16–20, 1974
17. Hershko C, Cook J.D., Finch C.A.: Storage iron kinetics. I.I.I. Study of desferrioxamine action by selective radioiron labels of R.E. and parenchymal cells. J Lab Clin Med 81: 876–886, 1973
18. Brown E.B., Hwang Y-F, Allgood J W: Studies of the site of action of deferoxamine. J Lab Clin Med 69: 382–404, 1967